S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
S&P 500   3,168.80 (+0.01%)
DOW   28,135.38 (+0.01%)
QQQ   207.19 (+0.33%)
AAPL   275.15 (+1.36%)
FB   194.11 (-1.34%)
MSFT   154.53 (+0.84%)
GOOGL   1,346.87 (-0.12%)
AMZN   1,760.94 (+0.03%)
CGC   20.68 (-2.13%)
NVDA   223.99 (-0.04%)
MU   51.20 (+0.45%)
BABA   204.91 (+0.20%)
GE   11.34 (-0.87%)
TSLA   358.39 (-0.36%)
T   38.26 (-0.23%)
AMD   41.15 (-3.38%)
ACB   2.63 (+1.15%)
F   9.23 (-0.97%)
PRI   136.56 (+0.04%)
NFLX   298.50 (+0.02%)
BAC   34.44 (-0.69%)
GILD   65.77 (-2.75%)
DIS   146.38 (-0.93%)
Log in

NASDAQ:MGTX - MeiraGTx Stock Price, Forecast & News

$21.02
+0.50 (+2.44 %)
(As of 12/13/2019 04:00 PM ET)
Today's Range
$20.24
Now: $21.02
$21.22
50-Day Range
$14.25
MA: $17.08
$21.43
52-Week Range
$8.53
Now: $21.02
$30.23
Volume214,200 shs
Average Volume165,123 shs
Market Capitalization$768.74 million
P/E RatioN/A
Dividend YieldN/A
Beta2.23
MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Read More…

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGTX
CUSIPN/A
CIKN/A
Phone646-860-7985

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.96 per share

Profitability

Net Income$-82,870,000.00

Miscellaneous

Employees68
Market Cap$768.74 million
Next Earnings Date3/24/2020 (Estimated)
OptionableNot Optionable

Receive MGTX News and Ratings via Email

Sign-up to receive the latest news and ratings for MGTX and its competitors with MarketBeat's FREE daily newsletter.


MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions

What is MeiraGTx's stock symbol?

MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."

How were MeiraGTx's earnings last quarter?

MeiraGTx Holdings PLC (NASDAQ:MGTX) released its earnings results on Thursday, November, 7th. The company reported ($0.30) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.53) by $0.23. The business had revenue of $3.58 million for the quarter. View MeiraGTx's Earnings History.

When is MeiraGTx's next earnings date?

MeiraGTx is scheduled to release their next quarterly earnings announcement on Tuesday, March 24th 2020. View Earnings Estimates for MeiraGTx.

What price target have analysts set for MGTX?

3 Wall Street analysts have issued 1 year price objectives for MeiraGTx's stock. Their forecasts range from $30.00 to $45.00. On average, they expect MeiraGTx's share price to reach $38.33 in the next twelve months. This suggests a possible upside of 82.4% from the stock's current price. View Analyst Price Targets for MeiraGTx.

What is the consensus analysts' recommendation for MeiraGTx?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MeiraGTx.

What are Wall Street analysts saying about MeiraGTx stock?

Here are some recent quotes from research analysts about MeiraGTx stock:
  • 1. According to Zacks Investment Research, "MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. " (11/13/2019)
  • 2. Chardan Capital analysts commented, "We rate MeiraGTx Buy on the forward- looking approach Meira management has taken to develop one of the broadest pipelines in all of AAV-based GT, including one with both lower-risk IRD opportunities for early wins and with higher-risk large-market opportunities that could generate profound investment returns." (9/23/2019)

Has MeiraGTx been receiving favorable news coverage?

Media coverage about MGTX stock has trended neutral this week, InfoTrie Sentiment reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. MeiraGTx earned a media sentiment score of 0.5 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for MeiraGTx.

Who are some of MeiraGTx's key competitors?

What other stocks do shareholders of MeiraGTx own?

Who are MeiraGTx's key executives?

MeiraGTx's management team includes the folowing people:
  • Dr. Alexandria Forbes, CEO, Pres & Director (Age 54)
  • Mr. Richard Brian Giroux, Chief Operating Officer (Age 46)
  • Dr. Stuart Naylor Ph.D., Chief Devel. Officer & Director (Age 56)
  • Ms. Katherine Edna Breedis C.F.A., CFA, CMT, Chief Financial Officer
  • Mr. Micah Zajic, VP of Corp. Devel.

When did MeiraGTx IPO?

(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI acted as the underwriters for the IPO and Chardan was co-manager.

Who are MeiraGTx's major shareholders?

MeiraGTx's stock is owned by many different of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (9.16%), State Street Corp (0.87%), Millennium Management LLC (0.56%), AE Wealth Management LLC (0.37%), Squarepoint Ops LLC (0.16%) and Russell Investments Group Ltd. (0.11%). Company insiders that own MeiraGTx stock include Life Sciences Maste Perceptive and Nicole Seligman. View Institutional Ownership Trends for MeiraGTx.

Which institutional investors are selling MeiraGTx stock?

MGTX stock was sold by a variety of institutional investors in the last quarter, including AE Wealth Management LLC and SG Americas Securities LLC. View Insider Buying and Selling for MeiraGTx.

Which institutional investors are buying MeiraGTx stock?

MGTX stock was purchased by a variety of institutional investors in the last quarter, including Orbimed Advisors LLC, Millennium Management LLC, State Street Corp, Squarepoint Ops LLC, Russell Investments Group Ltd., Bowling Portfolio Management LLC, CIBC Private Wealth Group LLC and Tower Research Capital LLC TRC. Company insiders that have bought MeiraGTx stock in the last two years include Life Sciences Maste Perceptive and Nicole Seligman. View Insider Buying and Selling for MeiraGTx.

How do I buy shares of MeiraGTx?

Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is MeiraGTx's stock price today?

One share of MGTX stock can currently be purchased for approximately $21.02.

How big of a company is MeiraGTx?

MeiraGTx has a market capitalization of $768.74 million. The company earns $-82,870,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. MeiraGTx employs 68 workers across the globe.View Additional Information About MeiraGTx.

What is MeiraGTx's official website?

The official website for MeiraGTx is http://www.meiragtx.com/.

How can I contact MeiraGTx?

MeiraGTx's mailing address is 450 East 29thStreet 15thFloor, NEW YORK NY, 10016. The company can be reached via phone at 646-860-7985 or via email at [email protected]


MarketBeat Community Rating for MeiraGTx (NASDAQ MGTX)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  139 (Vote Outperform)
Underperform Votes:  93 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about MeiraGTx and other stocks. Vote "Outperform" if you believe MGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/13/2019 by MarketBeat.com Staff

Featured Article: Equal Weight Rating

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel